We are making great strides in the fight against the corona-virus. In the beginning the disease had an 8,67% death rate. It is now down to 2.19%.

The corresponding numbers for U.S.A :  7.02%  death rate at the beginning of the disease. Ir is now down to 1.53%, a 78% decrease. With unrestricted availability to take HCQ+ we can reduce the death rate even further.

These are the numbers for every state.

State      Death rate max   7 day death rate now

Connecticut          9.62%     3.22%

New Hampshire  9.33%     5.2%

Missouri                8.96%     0.86% Prescribing hydroxychloroquine, chloroquine, and azithromycin for COVID-19 prophylactic is discouraged and not recommended. Prescribers include the diagnosis code or diagnosis with the prescription. Prescribers should consider limiting the amount prescribed.

Pennsylvania       8.81%     1.63%

Indiana                 8.77%     1.39%

New Jersey           8.73%     4.23%

New York State    8.64%     1.79%    Positive COVID-19 test result must be documented as part of the prescription.•Prohibits use of hydroxychloroquine or chloroquine for experimental or prophylactic use.

Michigan               8.58%     0.92%

South Carolina     8.52%     3.09%

Kansas                   7.69%     1.30% Strongly encourages vigilance in processing new prescriptions for chloroquine and hydroxychloroquine •Recommends that if used, chloroquine and hydroxychloroquine should be restricted to patients who are admitted to hospitals with COVID-19 infections.•Urges pharmacists to consider that patients currently taking hydroxychloroquine for FDA-approved indications (lupus, rheumatoid arthritis) could be affectedby increased prescribing and that supplies should be monitored by pharmacists for medication availability.•Recommends reaching out to prescribers to verify COVID-19 diagnosis.

West Virginia       7.68%     1.1%

Arizona                 7.62%     3.08%

Nevada                  7.53%     1.55% Restricts the dispensing of chloroquine and hydroxychloroquine. The patient must have a diagnosis of COVID-19 and the diagnosis is indicated on the prescription;

D.C.                         7.45%     0.86%

Oklahoma             7.29%     0.65%

Massachusetts     7.24%     4.55%

New Mexico         7.14%     1.97%

Maine                    7%           2%

Mississippi           7.06%     1.62%

Wisconsin            6.97%      0.93%

Colorado               6.96%     1.28%

Rhode Island       6.92%      0.88%

Alabama               6.61%     1.21%

Delaware              6.55%      2%

Maryland              6.16%     1.10%

Washington          5.69%     1.10%

Georgia                 5.24%     1.23%

Kentucky              5.02%     0.93% Prescriptions for chloroquine, hydroxychloroquine, mefloquine, and azithromycin may only be dispensed if: The prescription bears a written diagnosis from the prescriber consistent with its use;

Ohio                       4.97%     1.93% Prescriptions for either presumptive positive patients or prophylactic use of chloroquineor hydroxychloroquine related to COVID-19 is strictly prohibited unless the drugs are for use as part of a documented institutional review board-approved clinical trial to evaluate the safety and efficacy of the drugs to treat COVID-19

California             4.82%     1.47%

Arkansas              4.70%     1.20%

Oregon                  4.66%    1.76%

Illinois                  4,66%    1.12%

North Carolina   4.47%     1.27% Rule applies to hydroxychloroquine, chloroquine, lopinavir-ritonavir, ribavirin, darunavir, and azithromycin;•For above drugs, a pharmacist can only fill or refill a prescription if that prescription bears a written diagnosis from the prescriber consistent with its evidence for use;•If a patient has been diagnosed with COVID-19, any prescription of a drug listed above for the treatment of COVID-19 must: Indicate on the prescription that the patient has been diagnosed with COVID-19

Louisiana             4.18%     1.85% The boardoriginally issued an emergency rule to limit the dispensing of chloroquine and hydroxychloroquine to address shortages,but rescinded the rule after it received information about a significant donation and distribution of the drugs from the manufacturer, along with the removal of the drug from FDA’s drug shortage list.•It now encourages each pharmacy to exercise professional discretion to dispense limited quantities of the drug as appropriate

Florida                  4.02%     1.75%

Montana               4%          1.4%

Idaho                     3.70%     1.21%  No prescription for chloroquine or hydroxychloroquine may be dispensed except if the following apply: The prescription bears a written diagnosis from the prescriber consistent with evidence for its use;

Vermont                3.6%       1%

Texas                     3.60%     2.56% No prescription or medication order for chloroquine, hydroxychloroquine, mefloquine or azithromycin may be dispensed or distributed unless all the following apply:oThe prescription or medication order bears a written diagnosis from the prescriber consistent with the evidence for its use; The prescription or medication order is limited to no more than a 14-day supply unless the patient was previously established on the medication; and no refills may be permitted unless a new prescription or medication order is furnished

North Dakota       3.6%       0.8%

Minnesota            3.55%     0.70%

Tennessee            3.50%      0,71%

Alaska                   3.5%        1%

Iowa                      2.95%      1.27%

Hawaii                  2.8%        0.5%

Virginia                2.76%      1.40%

Utah                      1.66%      0.97%

South Dakota       1.1%       1.25%

Wyoming              1%           0.5%

Nebraska              0.82%     0.72%

For all states, June 15, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate donated to the Strategic National Stockpile to be used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation in a clinical trial was not feasible. The agency determined that the legal criteria for issuing an EUA are no longer met. Based on its ongoing analysis of the EUA and emerging scientific data, the FDA determined that chloroquine and hydroxychloroquine are unlikely to be effective in treating COVID-19 for the authorized uses in the EUA.

By the time the patient is hospitalized it may be too late to have any benefit of HCQ+ treatment. It works best as a prophylactic or taken as soon as the telltale sign occurs, loss of taste and smell, shortness of breath, etc. Then is the time to start the HCQ + Zn + Zmax treatment, even before a positive diagnosis is established.

Release HCQ to be sold as over the counter medication. For LUPUS and rheumatorial arthritis patients it is even prescribed to pregnant women and nursing mothers. It is that safe.

Here is the petition to the WhiteHouse to release it to over the counter dispensation. (19287 signed so far)